U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H17N3O.C4H6O4.H2O
Molecular Weight 379.4076
Optical Activity ( + )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Frovatriptan Succinate

SMILES

O.OC(=O)CCC(O)=O.CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(N)=O

InChI

InChIKey=CUETXFMONOSVJA-KLQYNRQASA-N
InChI=1S/C14H17N3O.C4H6O4.H2O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13;5-3(6)1-2-4(7)8;/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18);1-2H2,(H,5,6)(H,7,8);1H2/t9-;;/m1../s1

HIDE SMILES / InChI

Description

Frovatriptan succinate (trade name Frova) is a selective 5-hydroxytryptamine1 (5-HT1B/1D) receptor subtype agonist, and is used for the treatment of migraine attacks with or without aura in adults. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Serious but rare cardiac events have been reported in patients with risk factors predictive of coronary artery disease (CAD). These include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Originator

Approval Year

2001
194
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 62.0 nM [Ki]
Agonist
2678
 10.3 nM [Ki]
Agonist
2678
 4.4 nM [Ki]
Agonist
2678
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
FROVA

Approved Use

FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population.

Launch Date

2001
Primary
Approved
8429
FROVA

Approved Use

FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.44 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25092964
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FROVATRIPTAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
50.7 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25092964
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FROVATRIPTAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/25092964
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FROVATRIPTAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
FROVATRIPTAN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.8 mg single, intravenous
Highest studied dose
Dose: 0.8 mg
Route: intravenous
Route: single
Dose: 0.8 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028321
Page: S56
healthy, 21 - 37
n = 12
Health Status: healthy
Age Group: 21 - 37
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028321
Page: S56
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028321
Page: S56
40 mg single, oral
Highest studied dose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028321
Page: S56
healthy, 21 - 37
n = 12
Health Status: healthy
Age Group: 21 - 37
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028321
Page: S56
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028321
Page: S56
40 mg single, oral
Highest studied dose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028323
Page: S76
unhealthy, 40.4
n = 207
Health Status: unhealthy
Condition: Migraine
Age Group: 40.4
Sex: M+F
Population Size: 207
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028323
Page: S76
Sources:
https://pubmed.ncbi.nlm.nih.gov/12028323
Page: S76
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Disc. AE: Arrhythmia, Cerebral hemorrhage...
Other AEs: Myocardial ischemia, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Arrhythmia
Cerebral hemorrhage
Subarachnoid hemorrhage
Stroke
Gastrointestinal ischemia
Peripheral vasoconstriction
Serotonin syndrome
Other AEs:
Myocardial ischemia
Myocardial infarction
Prinzmetal angina
Chest pain
Throat pain
Neck pain
Jaw pain
Chest tightness
Throat tightness
Pressure
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Disc. AE: Splenic infarction, Raynaud's syndrome...
AEs leading to
discontinuation/dose reduction:
Splenic infarction
Raynaud's syndrome
Blood pressure high (grade 3)
Hypertensive crisis
Anaphylactic reaction (grade 4-5)
Anaphylactoid reaction (grade 4-5)
Angioedema (grade 4-5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
AEs

AEs

AESignificanceDosePopulation
Chest pain
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Chest tightness
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Jaw pain
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Myocardial infarction
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Myocardial ischemia
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Neck pain
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Pressure
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Prinzmetal angina
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Throat pain
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Throat tightness
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Arrhythmia Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Cerebral hemorrhage Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Gastrointestinal ischemia Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Peripheral vasoconstriction Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Serotonin syndrome Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Stroke Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Subarachnoid hemorrhage Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.1
Hypertensive crisis Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Raynaud's syndrome Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Splenic infarction Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Blood pressure high grade 3
Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Anaphylactic reaction grade 4-5
Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Anaphylactoid reaction grade 4-5
Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Angioedema grade 4-5
Disc. AE
7.5 mg 3 times / day multiple, oral
Recommended
Dose: 7.5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 7.5 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Migraine
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf
Page: p.3
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

inducer
781

substrate
1737
substrate
1037
inhibitor
1852

substrate
1217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C8/9
44

CYP2C19
1478

CYP2E1
882
CYP1A2
1054
CYP1A2
701

CYP4A
14
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2C19
1553
 no
CYP2C8/9
44
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A4
1925
 no
CYP3A4
1925
 no
CYP4A
33
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1037
 no
CYP2D6
1217
 no
CYP3A4
1737
 no
CYP1A2
1054
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1L2U95
AN PharmaTech
AN-5267
Alsachim
4232
http://www.alsachim.com/product-C5550-glo.bal-view.html
Angene
AGN-PC-0Q7KOZ
BLD Pharm
BD131596
http://www.bldpharm.com/products/158747-02-5.html
BOC Sciences
147009-08-3
BOC Sciences
158930-09-7
BOC Sciences
158930-17-7
Chem Scene
CS-0021309
ChemMol
44000939
http://www.chemmol.com/chemmol/44000939.html
ChemMol
49400089
http://www.chemmol.com/chemmol/49400089.html
ChemShuttle
159065
Chemieliva Pharmaceutical Co., Ltd
PBCM1202367
Compound Cloud
152943
Compound Cloud
77992
DC Chemicals
DC22890
http://www.dcchemicals.com/product_show-DC22890.html
Hangzhou APIChem Technology
AC-4258
MolPort
MolPort-046-196-805
Molnova
M12269
MuseChem
M105240
https://www.musechem.com/product/M105240.html
Norris Pharm
NSZB-A219176
NovoSeek
77992
Parchem
29025
http://www.parchem.com/chemical-supplier-distributor/Frovatriptan-019025.aspx
Selleck Chemicals
S5848
Sigma Aldrich
1286413
Sigma Aldrich
1286413|USP
Sigma Aldrich
SML1291
Sigma Aldrich
SML1291|SIGMA
Smolecule
S528497
http://www.smolecule.com/products/s528497
THE BioTek
bt-268779
https://www.thebiotek.com/product/inhibitors/bt-268779
THE BioTek
bt-406286
https://www.thebiotek.com/product/others/bt-406286
Toronto Research Chemicals
M198100
Wonderchem
WD05AWA
Wonderchem
WD05AWB
ZINC
ZINC000000018635
http://zinc15.docking.org/substances/ZINC000000018635
eMolecules
225791104
eMolecules
300452900
eMolecules
45916583
eMolecules
48667526
eMolecules
76760210
eNovation Chemicals
D380881
PubMed

PubMed

TitleDatePubMed
Evaluation of Frova, single-use intubation introducer, in a manikin. Comparison with Eschmann multiple-use introducer and Portex single-use introducer.
2004 Aug
Frovatriptan for the treatment of cluster headaches.
2004 Dec
Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.
2004 Jul
Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery.
2004 Jul
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
2004 Jul 27
Menstrual migraine: timing is everything.
2004 Jul 27
Gateways to clinical trials.
2004 Jun
Gateways to clinical trials.
2004 May
Tracheostomy must be individualized!
2004 Oct
Pharmacokinetics of frovatriptan in adolescent migraineurs.
2004 Oct
[Meta-analysis of triptan treatment in migraine].
2004 Sep
Gateways to clinical trials.
2004 Sep
Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe.
2004 Sep
Regulatory and functional interactions of plant growth regulators and plant glutathione S-transferases (GSTs).
2005
The use of triptans in the management of menstrual migraine.
2005
Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials.
2005 Dec
Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.
2005 Jan
Gateways to clinical trials.
2005 Mar
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
2005 Mar 8
Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects.
2005 May
[Tracheotomy and tracheostomy techniques].
2005 May
The use of multiattribute decision models in evaluating triptan treatment options in migraine.
2005 Sep
Frovatriptan-induced hypomania.
2005 Summer
[Clinical use of triptans in the management of migraine].
2006
Tracheal intubation using a classic laryngeal mask airway, Frova introducer, and pediatric bronchoscope.
2006 Dec
A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
2006 Dec 20
Shearing of a Frova Intubating Introducer by a Bronchocath double lumen tube.
2006 Feb
Clinical review: percutaneous dilatational tracheostomy.
2006 Feb
A validated chiral CE method for Frovatriptan, using cyclodextrin as chiral selector.
2006 Jun 16
Gateways to clinical trials.
2006 Nov
Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment.
2006 Oct
Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine.
2006 Sep
Editorial foreword.
2006 Sep
Airway management during microlaryngoscopic surgery with a Frova airway intubation catheter.
2006 Sep
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
2007
Frovatriptan review.
2007 Dec
Chiral separation of Frovatriptan isomers by HPLC using amylose based chiral stationary phase.
2007 Feb 1
Latest pain relief a combination of new and old.
2007 Jan
New pain management options: drugs.
2007 Jan
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Frovatriptan for the prevention of postdural puncture headache.
2007 Jul
Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.
2007 Jul
Efficacy of frovatriptan.
2007 Jun
Frova intubating catheter position can be determined with aspirating oesophageal detection device.
2007 Jun
Menstrually related migraine: breaking the cycle in your clinical practice.
2007 Oct
Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine.
2007 Oct
Efficacy of frovatriptan.
2007 Sep
Acute treatment and prevention of menstrually related migraine headache: evidence-based review.
2008 Apr 22
Triptans in pregnancy.
2008 Feb
Evaluation of clinical effectiveness of the Frova single-use tracheal tube introducer.
2008 Feb
Patents

Patents

20020049202
5
JP2002521446A
10
JP2011510954A
143

Sample Use Guides

In Vivo Use Guide
The recommended dose is a single tablet of FROVA (frovatriptan 2.5 mg) taken orally with fluids. If the headache recurs after initial relief, a second tablet may be taken, providing there is an interval of at least 2 hours between doses. The total daily dose of frovatriptan should not exceed 3 tablets (3 x 2.5 mg per day). The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Frovatriptan was investigated in human isolated basilar and coronary arteries in which the endothelium had been removed. Basilar arteries were obtained post mortem, and coronary arteries were obtained from patients undergoing heart transplant (recipient) or from donor hearts that were not suitable for transplant. Frovatriptan was a potent contractile agent in isolated basilar artery with a -log mean effective concentration (EC50) value of 7.86 +/- 0.07 and intrinsic activity of 1.25 +/- 0.10 relative to 5-HT (n = 4). In coronary arteries, frovatriptan produced contraction with -log EC50 values of 7.38 +/- 0.12 and 7.81 +/- 0.2 in recipient (n = 7) and donor (n = 3) arteries, respectively. The relative degree of contraction of frovatriptan was lower than that of 5-HT, with relative intrinsic activities of 0.42 +/- 0.06 and 0.40 +/- 0.09, respectively.
Unknown
Name Type Language
Frovatriptan Succinate
MART.   ORANGE BOOK   USAN   USP-RS  
USAN  
Official Name English
Frovatriptan succinate monohydrate
MI   WHO-DD  
Common Name English
SB 209509-AX
Code English
SB 209509 AX
Code English
FROVA
Code English
MIGUARD
Brand Name English
FROVELAN
Brand Name English
(+)-(R)-2,3,4,9-TETRAHYDRO-3-(METHYLAMINO)-1H-CARBAZOLE-6-CARBOXAMIDE BUTANEDIOATE (1:1), MONOHYDRATE
Systematic Name English
SB-209509-AX
Code English
FROVATRIPTAN SUCCINATE [USP-RS]
Common Name English
FROVATRIPTAN SUCCINATE MONOHYDRATE [MI]
Common Name English
FROVATRIPTAN SUCCINATE [MART.]
Common Name English
VML 251
Code English
(+)-(R)-5,6,7,8-TETRAHYDRO-6-(METHYLAMINO)CARBAZOLE-3-CARBOXAMIDE SUCCINATE (1:1), MONOHYDRATE
Systematic Name English
FROVATRIPTAN SUCCINATE [USAN]
Common Name English
SB-209509AX
Code English
MIGARD
Brand Name English
FROVATRIPTAN SUCCINATE HYDRATE
Common Name English
BUTANEDIOIC ACID, COMPD. WITH (R)-2,3,4,9-TETRAHYDRO-3-(METHYLAMINO)-1H-CARBAZOLE-6-CARBOXAMIDE (1:1), MONOHYDRATE
Systematic Name English
Frovatriptan succinate monohydrate [WHO-DD]
Common Name English
VML-251
Code English
FROVATRIPTAN SUCCINATE [ORANGE BOOK]
Common Name English
NSC-760422
Code English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1286413
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
RXCUI
322249
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m5571
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C47544
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL1279
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
USAN
KK-26
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
FDA UNII
D28J6W18HY
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
DRUG BANK
DBSALT001958
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
CAS
158930-17-7
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
WIKIPEDIA
Frovatriptan succinate
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
SMS_ID
100000153228
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
PUBCHEM
152943
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
DAILYMED
D28J6W18HY
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID2049056
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
EVMPD
SUB22174
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
NSC
760422
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
EVMPD
SUB127149
Created by admin on Fri Dec 15 15:57:50 GMT 2023 , Edited by admin on Fri Dec 15 15:57:50 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of FROVATRIPTAN
PARENT (SALT/SOLVATE)
Structure of SUCCINIC ACID
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966